Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Zevra Therapeutics, Inc. (ZVRA) had Normalized Income after Taxes of $83.23M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$106.47M |
|
$77.58M |
|
$16.48M |
|
$89.99M |
|
$169.41M |
|
$-62.94M |
|
$149.62M |
|
$86.68M |
|
$86.68M |
|
$83.23M |
|
$83.23M |
|
$83.23M |
|
|
Normalized Income after Taxes |
$83.23M |
$-62.94M |
|
$-3.31M |
|
55.31M |
|
57.26M |
|
$1.40 |
|
$1.35 |
|
| Balance Sheet Financials | |
$223.01M |
|
$0.49M |
|
$61.72M |
|
$284.73M |
|
$39.28M |
|
$61.93M |
|
$90.80M |
|
$130.07M |
|
$154.66M |
|
$143.53M |
|
$154.66M |
|
56.85M |
|
| Cash Flow Statement Financials | |
$-1.60M |
|
$18.13M |
|
$12.06M |
|
$33.78M |
|
$62.41M |
|
$28.62M |
|
$12.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.68 |
|
-- |
|
-- |
|
0.29 |
|
0.40 |
|
84.52% |
|
-59.12% |
|
-59.12% |
|
-3.11% |
|
81.41% |
|
72.87% |
|
$-1.99M |
|
-- |
|
-- |
|
-- |
|
0.37 |
|
9.47 |
|
4.58 |
|
79.73 |
|
53.82% |
|
57.99% |
|
29.23% |
|
38.43% |
|
$2.72 |
|
$-0.03 |
|
$-0.03 |
|